Thelansis

Premenstrual Dysphoric Disorder (PMDD) Market Outlook Thelansis’s “Premenstrual Dysphoric Disorder (PMDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Premenstrual Dysphoric Disorder (PMDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have th...

  Premenstrual Dysphoric Disorder (PMDD) Market Outlook Thelansis’s “Premenstrual Dysphoric Disorder (PMDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Premenstrual Dysphoric Disorder (PMDD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Premenstrual Dysphoric Disorder (PMDD) Overview Premenstrual Dysphoric Disorder (PMDD) is a depressive disorder categorized as “not otherwise specified” in the Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Association. It is characterized by mood, appetite, energy, and cognitive changes that manifest during the menstrual cycle’s late luteal (pr...

  Premenstrual Dysphoric Disorder (PMDD) is a depressive disorder categorized as "not otherwise specified" in the Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Association. It is characterized by mood, appetite, energy, and cognitive changes that manifest during the menstrual cycle's late luteal (premenstrual) phase and subside shortly after the onset of menses. The onset of symptoms is closely linked to the late luteal phase, which coincides with declining levels of estrogen and progesterone. Symptom relief typically occurs during the initial days of the follicular phase when estrogen levels increase due to ovarian follicular growth. The exact cause of PMS/PMDD remains unknown. However, certain risk factors are associated with the development of the condition, some of which have been well-established, while others are still speculative. Proven Risk Factors: Past traumatic events: Traumatic experiences and preexisting...